collection
MENU ▼
Read by QxMD icon Read
search

cardiotoxicity

shared collection
127 papers 0 to 25 followers
By Elvis Amao Internal Medicine , Cardiology and infectious diseases
https://www.readbyqxmd.com/read/29764506/cardiotoxicity-of-5-fluorouracil-and-capecitabine-in-chinese-patients-a-prospective-study
#1
Jianjun Peng, Chao Dong, Chang Wang, Weihua Li, Hao Yu, Min Zhang, Qun Zhao, Bo Zhu, Jun Zhang, Wenliang Li, Fenghua Wang, Qiong Wu, Wenhao Zhou, Ying Yuan, Meng Qiu, Gong Chen
BACKGROUND: 5-Fluorouracil (5-FU) and capecitabine-associated cardiotoxicity ranging from asymptomatic electrocardiography (ECG) abnormalities to severe myocardial infarction has been reported in a number of studies, but such cardiotoxicity in Chinese patients with malignant diseases has not been investigated to date. In the present study, we aimed to prospectively evaluate the incidence rates and clinical manifestations of 5-FU- and capecitabine-associated cardiotoxicity in cancer patients recruited from multiple centers in China...
May 11, 2018: Cancer communications
https://www.readbyqxmd.com/read/29737278/determining-the-genetic-basis-of-anthracycline-cardiotoxicity-by-response-qtl-mapping-in-induced-cardiomyocytes
#2
David A Knowles, Courtney K Burrows, John D Blischak, Kristen M Patterson, Daniel J Serie, Nadine Norton, Carole Ober, Jonathan K Pritchard, Yoav Gilad
Anthracycline-induced cardiotoxicity (ACT) is a key limiting factor in setting optimal chemotherapy regimes, with almost half of patients expected to develop congestive heart failure given high doses. However, the genetic basis of sensitivity to anthracyclines remains unclear. We created a panel of iPSC-derived cardiomyocytes from 45 individuals and performed RNA-seq after 24h exposure to varying doxorubicin dosages. The transcriptomic response is substantial: the majority of genes are differentially expressed and over 6000 genes show evidence of differential splicing, the later driven by reduced splicing fidelity in the presence of doxorubicin...
May 8, 2018: ELife
https://www.readbyqxmd.com/read/29737294/effect-of-anthracycline-combined-with-aerobic-exercise-on-the-treatment-of-breast-cancer
#3
Zhijun Ma
Anthracycline is a standard drug for the treatment of breast cancer. However, anthracycline has great cardiotoxicity. Some patients stop chemotherapy during severe chemotherapy and even undergo serious heart failure. At the same time, there is lack of clinical study on whether aerobic exercise can reduce the cardiotoxicity of chemotherapy drugs. The purpose of this study is to investigate the effects of aerobic exercise on the cardiac function of patients with breast cancer after anthracycline therapy. The results showed that the control group LVEF decreased significantly...
May 2018: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29737469/serum-mir-30c-level-predicted-cardiotoxicity-in-non-small-cell-lung-cancer-patients-treated-with-bevacizumab
#4
Fang Zhou, Xike Lu, Xun Zhang
Cardiotoxicity is a common adverse effect induced by drug chemotherapy. miR-30c has been reported to be involved in the progress of heart diseases. In the present study, miR-30c was used to predict the cardiotoxicity in non-small cell lung cancer (NSCLC) patients treated with bevacizumab chemotherapy. Eighty NSCLC patients were included in this study. Serum miR-30c levels were detected at pre-chemotherapy, during-chemotherapy (the 2nd, 4th, and 8th week) and 1 month after chemotherapy. miR-30c expression was elevated with the duration of the chemotherapy cycle and decreased 1 month after chemotherapy...
May 8, 2018: Cardiovascular Toxicology
https://www.readbyqxmd.com/read/29747541/risk-benefit-of-dexrazoxane-for-preventing-anthracycline-related-cardiotoxicity-re-evaluating-the-european-labeling
#5
Peter Reichardt, Marie-Dominique Tabone, Jaume Mora, Bruce Morland, Robin L Jones
Dexrazoxane can prevent anthracycline-associated cardiotoxicity. However, in 2011, its use in children was contraindicated by the EMA over concerns of increased risk of infection, myelosuppression and second primary malignancies, and because its efficacy in children had not then been established. We review here the evidence published since 2011, which confirms that dexrazoxane is an effective cardioprotectant in children and adolescents, is not associated with an increased risk of second primary malignancies or excess early or late mortality and does not impair chemotherapy efficacy...
May 11, 2018: Future Oncology
https://www.readbyqxmd.com/read/29723895/anticancer-drug-related-nonvalvular-atrial-fibrillation-challenges-in-management-and-antithrombotic-strategies
#6
Antonella Tufano, Maurizio Galderisi, Luca Esposito, Valentina Trimarco, Daniela Sorriento, Guy Gerusalem, Marco Picardi, Patrizio Lancellotti, Fabrizio Pane
Cancer patients may experience nonvalvular atrial fibrillation (AF) as a manifestation of cardiotoxicity. AF may be a direct effect of a neoplasm or, more often, appear as a postsurgical complication, especially after thoracic surgery. AF may also develop as a consequence of anticancer therapy (chemotherapy or radiotherapy), a condition probably underestimated. Cancer patients with AF require a multidisciplinary approach involving oncologists/hematologists, cardiologists, and coagulation experts. An echocardiogram should be performed to detect possible abnormalities of left ventricular systolic and diastolic function, as well as left atrial dilation and the existence of valvular heart disease, to determine pretest probability of sinus rhythm restoration, and identify the best treatment...
May 3, 2018: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/29713898/pharmacogenetics-of-chemotherapy-induced-cardiotoxicity
#7
REVIEW
Vivian Y Chang, Jessica J Wang
PURPOSE OF REVIEW: The goal of this review is to summarize current understanding of pharmacogenetics and pharmacogenomics in chemotherapy-induced cardiotoxicity. RECENT FINDINGS: Most of the studies rely on in vitro cytotoxic assays. There have been several smaller scale candidate gene approaches and a handful of genome-wide studies linking genetic variation to susceptibility to chemotherapy-induced cardiotoxicity. Currently, pharmacogenomic testing of all childhood cancer patients with an indication for doxorubicin or daunorubicin therapy for RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 variants is recommended...
April 30, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29708912/chemotherapy-induced-cardiotoxicity-new-insights-into-mechanisms-monitoring-and-prevention
#8
Christian Cadeddu Dessalvi, Martino Deidda, Donato Mele, Pier P Bassareo, Roberta Esposito, Ciro Santoro, Maria Lembo, Maurizio Galderisi, Giuseppe Mercuro
: Chemotherapy-induced cardiotoxicity (CTX) remains a determining factor for the quality of life and mortality of patients treated with potentially cardiotoxic drugs. Considerable advances have been made in this field with increase in awareness regarding chemotherapy-induced CTX, which has changed the treatment approach to include cardiovascular risk among the first factors to be evaluated before therapy. Moreover, a better understanding of the pathophysiology of chemotherapy-induced CTX has also facilitated early identification of patients at risk with the help of new imaging technologies...
April 26, 2018: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/29540327/carvedilol-for-prevention-of-chemotherapy-related-cardiotoxicity-the-ceccy-trial
#9
Mônica Samuel Avila, Silvia Moreira Ayub-Ferreira, Mauro Rogerio de Barros Wanderley, Fatima das Dores Cruz, Sara Michelly Gonçalves Brandão, Vagner Oliveira Carvalho Rigaud, Marília Harumi Higuchi-Dos-Santos, Ludhmila Abrahão Hajjar, Roberto Kalil Filho, Paulo Marcelo Hoff, Marina Sahade, Marcela S M Ferrari, Romulo Leopoldo de Paula Costa, Max Senna Mano, Cecilia Beatriz Bittencourt Viana Cruz, Maria Cristina Abduch, Marco Stephan Lofrano Alves, Guilherme Veiga Guimaraes, Victor Sarli Issa, Marcio Sommer Bittencourt, Edimar Alcides Bocchi
BACKGROUND: Anthracycline (ANT) chemotherapy is associated with cardiotoxicity. Prevention with β-blockers remains controversial. OBJECTIVES: This prospective, randomized, double-blind, placebo-controlled study sought to evaluate the role of carvedilol in preventing ANT cardiotoxicity. METHODS: The authors randomized 200 patients with HER2-negative breast cancer tumor status and normal left ventricular ejection fraction (LVEF) referred for ANT (240 mg/m2 ) to receive carvedilol or placebo until chemotherapy completion...
May 22, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29563880/antineoplastic-drug-induced-cardiotoxicity-a-redox-perspective
#10
REVIEW
Gilda Varricchi, Pietro Ameri, Christian Cadeddu, Alessandra Ghigo, Rosalinda Madonna, Giancarlo Marone, Valentina Mercurio, Ines Monte, Giuseppina Novo, Paolo Parrella, Flora Pirozzi, Antonio Pecoraro, Paolo Spallarossa, Concetta Zito, Giuseppe Mercuro, Pasquale Pagliaro, Carlo G Tocchetti
Antineoplastic drugs can be associated with several side effects, including cardiovascular toxicity (CTX). Biochemical studies have identified multiple mechanisms of CTX. Chemoterapeutic agents can alter redox homeostasis by increasing the production of reactive oxygen species (ROS) and reactive nitrogen species RNS. Cellular sources of ROS/RNS are cardiomyocytes, endothelial cells, stromal and inflammatory cells in the heart. Mitochondria, peroxisomes and other subcellular components are central hubs that control redox homeostasis...
2018: Frontiers in Physiology
https://www.readbyqxmd.com/read/29567630/anthracycline-induced-cardiotoxicity-a-multicenter-randomised-trial-comparing-two-strategies-for-guiding-prevention-with-enalapril-the-international-cardiooncology-society-one-trial
#11
Daniela Cardinale, Fabio Ciceri, Roberto Latini, Maria Grazia Franzosi, Maria Teresa Sandri, Maurizio Civelli, GianFranco Cucchi, Elisabetta Menatti, Maurizio Mangiavacchi, Raffaele Cavina, Enrico Barbieri, Stefania Gori, Alessandro Colombo, Giuseppe Curigliano, Michela Salvatici, Antonio Rizzo, Francesco Ghisoni, Alessandra Bianchi, Cristina Falci, Michele Aquilina, Andrea Rocca, Anna Monopoli, Carlo Milandri, Giuseppe Rossetti, Marco Bregni, Marco Sicuro, Alessandra Malossi, Daniele Nassiacos, Claudio Verusio, Monica Giordano, Lidia Staszewsky, Simona Barlera, Enrico B Nicolis, Michela Magnoli, Serge Masson, Carlo M Cipolla
BACKGROUND: Troponin changes over time have been suggested to allow for an early diagnosis of cardiac injury ensuing cancer chemotherapy; cancer patients with troponin elevation may benefit of therapy with enalapril. It is unknown whether a preventive treatment with enalapril may further increase the benefit. METHODS: The International CardioOncology Society-one trial (ICOS-ONE) was a controlled, open-label trial conducted in 21 Italian hospitals. Patients were randomly assigned to two strategies: enalapril in all patients started before chemotherapy (CT; 'prevention' arm), and enalapril started only in patients with an increase in troponin during or after CT ('troponin-triggered' arm)...
May 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29608498/cardioprotection-in-the-modern-era-of-cancer-chemotherapy
#12
Anuradha Godishala, Shu Yang, Aarti Asnani
The current arsenal of cancer chemotherapy is broad and rapidly expanding and includes conventional cytotoxic agents and targeted and immune-based therapies. As cancer survival rates have improved, the acute and latent cardiotoxicities of chemotherapy have emerged as important contributors to morbidity and mortality in cancer survivors. All chemotherapeutic agents have the potential for cardiac complications, with manifestations ranging from subclinical left ventricular dysfunction and asymptomatic QT prolongation, to congestive heart failure, myocardial ischemia, myocarditis, arrhythmia, and sudden cardiac death...
May 2018: Cardiology in Review
https://www.readbyqxmd.com/read/29610292/renin-angiotensin-system-inhibitors-to-mitigate-cancer-treatment-related-adverse-events
#13
Matthias Pinter, Wilhelmus J Kwanten, Rakesh K Jain
Treatment-related side effects are a major clinical problem in cancer treatment. They lead to reduced compliance to therapy as well as increased morbidity and mortality. Well-known are the sequelae of chemotherapy on the heart, especially in childhood cancer survivors. Therefore, measures to mitigate the adverse events of cancer therapy may improve health and quality of life in cancer patients, both in short and long term. The renin angiotensin system (RAS) affects all hallmarks of cancer, and blockage of the RAS is associated with an improved outcome in several cancer types...
April 2, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29616409/cardiotoxicity-in-hematological-diseases-are-the-tyrosine-kinase-inhibitors-imatinib-and-nilotinib-safe
#14
Ana Rita G Francisco, Daniela Alves, Cláudio David, Lurdes Guerra, Fausto J Pinto, Ana G Almeida
Chemotherapy-induced cardiotoxicity is a growing concern. The cardiotoxic impact of new drugs such as tyrosine kinase inhibitors is unknown, especially the ones used for chronic myeloid leukemia. We aim to evaluate nilotinib- and imatinib-induced cardiotoxicity. Single-center prospective study of consecutive patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors was conducted during 2015. Patients underwent an initial clinical, laboratorial and echocardiographic evaluation, repeated after 1 year...
April 3, 2018: Cardiovascular Toxicology
https://www.readbyqxmd.com/read/29629020/diagnosis-treatment-and-prevention-of-cardiovascular-toxicity-related-to-anti-cancer-treatment-in-clinical-practice-an-opinion-paper-from-the-working-group-on-cardio-oncology-of-the-korean-society-of-echocardiography
#15
REVIEW
Hyungseop Kim, Woo-Baek Chung, Kyoung Im Cho, Bong-Joon Kim, Jeong-Sook Seo, Seong-Mi Park, Hak Jin Kim, Ju-Hee Lee, Eun Kyoung Kim, Ho-Joong Youn
Cardiovascular (CV) toxicity associated with anti-cancer treatment is commonly encountered and raises critical problems that often result in serious morbidity or mortality. Most cardiac toxicities are related to the cumulative dose of chemotherapy; however, the type of chemotherapy, concomitant agents, and/or conventional CV risk factors have been frequently implicated in CV toxicity. Approximately half of the patients exhibiting CV toxicity receive an anthracycline-based regimen. Therefore, serologic biomarkers or cardiac imagings are important during anti-cancer treatment for early detection and the decision of appropriate management of cardiotoxicity...
March 2018: Journal of Cardiovascular Ultrasound
https://www.readbyqxmd.com/read/29434549/protective-mechanism-of-hydrogen-sulfide-against-chemotherapy-induced-cardiotoxicity
#16
REVIEW
Shuxu Du, Yaqian Huang, Hongfang Jin, Tianyou Wang
Over the past few decades, the number of long term survivors of childhood cancers has been increased exponentially. However, among these survivors, treatment-related toxicity, especially cardiotoxicity, is becoming the essential cause of morbidity and mortality. Thus, preventing the treatment-related adverse effects is important to increase the event free survival during the treatment of cancer in children and adolescents. Accumulating evidence has demonstrated that hydrogen sulfide (H2 S) exerts a protective role on cardiomyocytes through a variety of mechanisms...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29473044/cardiotoxicity-of-anticancer-therapeutics
#17
REVIEW
Jerry Dong, Hong Chen
As cancer therapeutics continues to improve and progress, the adverse side effects associated with anticancer treatments have also attracted more attention and have become extensively explored. Consequently, the importance of posttreatment follow-ups is becoming increasingly relevant to the discussion. Contemporary treatment methods, such as tyrosine kinase inhibitors, anthracycline chemotherapy, and immunotherapy regimens are effective in treating different modalities of cancers; however, these reagents act through interference with DNA replication or prevent DNA repair, causing endothelial dysfunction, generating reactive oxygen species, or eliciting non-specific immune responses...
2018: Frontiers in Cardiovascular Medicine
https://www.readbyqxmd.com/read/29262402/sacubitril-valsartan-in-field-practice-patients-with-advanced-heart-failure-a-monocentric-italian-experience
#18
Antonella Vincenzi, Francesca Cesana, Antonio Cirò, Laura Garatti, Felice Achilli
Patients with advanced heart failure (HF) experience a continuous decline in quality of life and have a very poor prognosis. Moreover, due to numerous comorbidities present in these patients, transplantation and left ventricular assist devices are usually impracticable in clinical practice. In this challenging setting, administration of inotropic agents may be the only possible therapy; however, this treatment requires frequent hospitalizations. Our hypothesis is that sacubitril/valsartan, given its marked efficacy and manageability, can be safely used in clinical practice in this setting, potentially reducing hospitalizations and the need for inotropic support...
2017: Cardiology
https://www.readbyqxmd.com/read/29217634/anthracycline-cardiotoxicity-an-update-on-mechanisms-monitoring-and-prevention
#19
REVIEW
Peter A Henriksen
Anthracycline chemotherapy causes dose-related cardiomyocyte injury and death leading to left ventricular dysfunction. Clinical heart failure may ensue in up to 5% of high-risk patients. Improved cancer survival together with better awareness of the late effects of cardiotoxicity has led to growing recognition of the need for surveillance of anthracycline-treated cancer survivors with early intervention to treat or prevent heart failure. The main mechanism of anthracycline cardiotoxicity is now thought to be through inhibition of topoisomerase 2β resulting in activation of cell death pathways and inhibition of mitochondrial biogenesis...
December 7, 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/29166731/-research-progress-on-the-prevention-and-therapy-for-chemotherapy-related-cardiotoxicity-and-cardiomyopathy
#20
H Lin, S Zuo, N Liu
No abstract text is available yet for this article.
November 24, 2017: Zhonghua Xin Xue Guan Bing za Zhi
label_collection
label_collection
6870
1
2
2017-11-27 13:46:41
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"